Genomic and proteomic analysis has driven research on disease pathology for the past several decades, leading to breakthroughs in disease detection and treatment, particularly in cancer care. Despite ...

With the evolution of scalability of peripheral blood protein glycosylation, research has expanded for new biomarkers. Most strategies for liquid-biopsy-based early cancer screening and detection ...

A firm developing a special protein-targeting platform for use in biotech drugs has signed a deal with Swiss drugmaker Roche potentially worth nearly $200 million or more. Cambridge, ...

SAN FRANCISCO--(BUSINESS WIRE)--InterVenn Biosciences, the leader in applied glycoproteomics, today announced that it will present new clinical data detailing the success of its novel approach to ...

Protein glycosylation is a fundamental biological process that regulates various cellular functions, yet its study has been hampered by the complexity and low abundance of glycoproteins. In a ...

While we often think of diseases as caused by foreign bodies -- bacteria or viruses -- there are hundreds of diseases affecting humans that result from errors in cellular production of its proteins. A ...

Glycosylated proteins are often overexpressed in tumor cells and thus could serve as tumor markers, especially those with the interesting molecule sialic acid as their sugar moiety. Scientists now ...

SAN FRANCISCO--(BUSINESS WIRE)--InterVenn Biosciences today announced multiple achievements in its development of AI-enabled glycoproteomics, as it looks to solving difficult challenges in various ...

This study is led by Dr. Haojie Lu from Fudan University. Researchers introduce a new glycoproteomics approach called high-throughput intact glycopeptides quantitation strategy (HTiGQs). They used N,N ...

Intervenn Biosciences raised $201 million in a series C financing led by new investors Softbank Group, Heritage Provider Network, Irving Investors and Highside Capital Management. The proceeds are ...